Phasebio Pharmaceuticals Quick Ratio (PHAS) starting from the second quarter 2022 to second quarter 2021, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Phasebio Pharmaceuticals Inc.  (NASDAQ: PHAS)

Phasebio Pharmaceuticals's Quick Ratio

PHAS's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2022, Quick Ratio fell to 0.32 a new company low.

Within Major Pharmaceutical Preparations industry 592 other companies have achieved higher Quick Ratio than Phasebio Pharmaceuticals in second quarter 2022. While Quick Ratio total ranking in the second quarter 2022 has deteriorated compared to the prior quarter from 3420 to 4484.

Explain Quick Ratio?
How much Cash & cash equivalents PHAS´s has?
What are PHAS´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

PHAS Quick Ratio (Jun 30 2022)
Q2		 (Mar 31 2022)
Q1		 (Dec 31 2021)
Q4		 (Sep 30 2021)
Q3		 (Jun 30 2021)
Q2
Y / Y Current Liabilities Change 52.58 % 92.47 % 39.26 % 187.43 % 34.99 %
Y / Y Cash & cash equivalent Change -87.89 % -75.72 % 48.64 % 43.21 % 21.56 %
Quick Ratio MRQ 0.32 0.86 2.01 2.63 3.99
PHAS's Total Ranking # 4484 # 3420 # 2630 # 2173 # 1778
Seq. Current Liabilities Change 13.79 % 4.1 % -2.91 % 32.66 % 43.54 %
Seq. Cash & cash equivalent Change -58.24 % -55.29 % -25.83 % -12.57 % -16.25 %



Quick Ratio second quarter 2022 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 593
Healthcare Sector # 1141
Overall Market # 4351


Quick Ratio Statistics
High Average Low
22.41 7.44 0.32
(Sep 30 2019)   (Jun 30 2022)




Financial Statements
Phasebio Pharmaceuticals's Current Liabilities $ 25 Millions Visit PHAS's Balance sheet
Phasebio Pharmaceuticals's Cash & cash equivalent $ 8 Millions Visit PHAS's Balance sheet
Source of PHAS's Sales Visit PHAS's Sales by Geography


Cumulative Phasebio Pharmaceuticals's Quick Ratio

PHAS's Quick Ratio for the trailling 12 Months

PHAS Quick Ratio

 (Jun 30 2022)
12 Months		 (Mar 31 2022)
12 Months		 (Dec 31 2021)
12 Months		 (Sep 30 2021)
12 Months		 (Jun 30 2021)
12 Months
Y / Y Current Liabilities TTM Growth 77.79 % 75.48 % 74.28 % 90.45 % 67.82 %
Y / Y Cash & cash equivalent TTM Growth -40.33 % -8.18 % 33.14 % 0.03 % -22.12 %
Quick Ratio TTM 1.41 2.26 3.44 3.54 4.19
Total Ranking TTM # 3677 # 5377 # 5300 # 5255 # 5243
Seq. Current Liabilities TTM Growth 10.61 % 14.94 % 9.2 % 28.06 % 9.18 %
Seq. Cash & cash equivalent TTM Growth -31.25 % -24.32 % 6.05 % 8.14 % 5.79 %

Quick ratio ranking by company, industry and sector >> Back to PHAS Financial Strength Comparisons >> Go to Compare PHAS Quick Ratio to its Competitors

On the trailing twelve months basis Due to increase in Current Liabilities in the Q2 2022 to $24.68 millions, cumulative Quick Ratio decreased to 1.41 below the Phasebio Pharmaceuticals Inc. average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 546 other companies have achieved higher Quick Ratio than Phasebio Pharmaceuticals. While Quick Ratio overall ranking has improved so far to 3677, from total ranking during the twelve months ending first quarter 2022 at 5377.

Explain Quick Ratio?
How much Cash & cash equivalents PHAS´s has?
What are PHAS´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 547
Healthcare Sector # 1061
Within the Market # 3677


trailing twelve months Quick Ratio Statistics
High Average Low
14.19 6.13 1.3
(Sep 30 2019)   (Jun 30 2022)




Companies with similar Quick Ratio in the quarter ending Jun 30 2022, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2022 MRQ Cash & cash equivalentJun 30 2022 MRQ Current Liabilities
Zoetis Inc   0.87 $ 2,652.000  Millions$ 3,051.000  Millions
Novan Inc   0.84 $ 37.302  Millions$ 44.257  Millions
Lannett Company Inc  0.84 $ 87.854  Millions$ 104.940  Millions
Biohaven Ltd   0.82 $ 553.486  Millions$ 671.956  Millions
Nature s Sunshine Products inc   0.82 $ 56.344  Millions$ 69.119  Millions
Innovation Pharmaceuticals Inc   0.81 $ 3.885  Millions$ 4.808  Millions
Thorne Healthtech Inc   0.80 $ 27.811  Millions$ 34.569  Millions
Sonnet Biotherapeutics Holdings Inc   0.80 $ 5.225  Millions$ 6.505  Millions
Lifevantage Corp  0.78 $ 20.190  Millions$ 25.728  Millions
Clovis Oncology inc   0.78 $ 94.579  Millions$ 121.272  Millions
Phibro Animal Health Corporation  0.77 $ 91.248  Millions$ 118.428  Millions
Cumberland Pharmaceuticals Inc   0.77 $ 18.217  Millions$ 23.740  Millions
Heron Therapeutics Inc   0.76 $ 83.538  Millions$ 109.498  Millions
Abbott Laboratories  0.75 $ 9,290.000  Millions$ 12,392.000  Millions
Ibio inc   0.75 $ 22.705  Millions$ 30.436  Millions
Intercure Ltd   0.74 $ 66.093  Millions$ 88.863  Millions
Gelesis Holdings Inc   0.72 $ 25.341  Millions$ 35.027  Millions
Pfizer Inc  0.70 $ 33,304.000  Millions$ 47,410.000  Millions
Allarity Therapeutics Inc   0.67 $ 7.677  Millions$ 11.462  Millions
Xencor Inc  0.66 $ 49.410  Millions$ 75.041  Millions
Ani Pharmaceuticals Inc  0.66 $ 63.385  Millions$ 96.312  Millions
Avalo Therapeutics Inc   0.65 $ 11.263  Millions$ 17.395  Millions
Journey Medical Corp  0.63 $ 38.142  Millions$ 60.100  Millions
Bristol myers Squibb Company  0.63 $ 13,228.000  Millions$ 20,915.000  Millions
Chimerix Inc   0.63 $ 14.705  Millions$ 23.271  Millions
Supernus Pharmaceuticals inc   0.61 $ 360.787  Millions$ 589.775  Millions
Humanigen Inc  0.61 $ 47.046  Millions$ 76.990  Millions
Akebia Therapeutics Inc   0.61 $ 143.893  Millions$ 237.401  Millions
Vireo Growth Inc.  0.60 $ 16.971  Millions$ 28.166  Millions
Aquestive Therapeutics Inc   0.60 $ 17.695  Millions$ 29.636  Millions

Date modified: 2026-09-26T07:35:42+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.